This strategic plan was developed during 2021 with input from a workgroup composed of diverse voices from staff of the California Department of Public Health, key stakeholders, and people with lived experience of HIV, HCV, and/or STIs. The document provides a high-level overview of the strategies for the State's work over the next 5 years to end the syndemic of HIV, HCV, and STIs in California, in partnership with people at regional and local levels. The plan uses a social determinants of health framework, and centers equity and racial justice as a core part of the mission. Phase 2 of this project will be to work with stakeholders throughout the state in 2022, to create a blueprint document that turns these high-level strategies into concrete, realistic activities that will help realize the plan's goals.

This scientifically accurate and well-cited guide to COVID-19 vaccination is written in lay language, and was developed for a client to distribute to vaccine hesitant staff in their workplace, once the Delta variant began to spread in the United States.

Facente Consulting worked with Hamilton Families throughout early 2021 to develop a strategic plan that would highlight their efforts to help homeless families in the Bay Area recover from the impacts of the COVID-19 pandemic, and thrive together with a safe and stable place to live.

Developed for CDC on behalf of the California Department of Public Health and health department staff of Alameda, Orange, Riverside, Sacramento, San Bernardino, and San Diego counties, in response to CDC PS 19-1906, calling for 5-year plans to end the HIV epidemic in high-impact jurisdictions.

This plan was written by Facente Consulting over a one-year period, with the input of stakeholders from the San Francisco Department of Public Health, local community organizations, and most importantly members of communities highly impacted by these epidemics in San Francisco.

Developed for San Francisco's collective impact initiative to eliminate hepatitis C as a public health threat, End Hep C SF.

This issue brief was commissioned by Battery Powered, the social engagement "giving program" within San Francisco's social club The Battery. Issue briefs are created once per quarter to educate members on critical societal issues, to help guide foundational giving and improve their community.

This document is the public summary of the more comprehensive strategic plan developed by Facente Consulting for the San Francisco AIDS Foundation during a year-long process.

This Community Health Needs Assessment (CHNA) was prepared by Facente Consulting as part of the tri-annual CHNA requirement for this non-profit offering residential medical services for older adults in San Francisco.

This report is a summary of the World Health Organization/UNAIDS convening of the international Working Group on HIV Incidence, held in Boston, MA in 2018. Shelley Facente served as WHO's official rapporteur for the meeting and developed this report.

Developed for the California Department of Public Health, this plan was released in September 2016 and has been the guiding force for the State of California's quest to "Get to Zero" with HIV.

Prepared for the Treasure Island Homeless Development Initiative (now One Treasure Island) and the Treasure Island Development Authority (TIDA), this report provided guidance for the protection of young people already living on Treasure Island in San Francisco during its $1.6 billion redevelopment.

Developed for the Oakland TGA Collaborative Community Planning Council, in response to three questions of focus for HIV planning in Alameda and Contra Costa Counties, CA.

Developed for the San Francisco Department of Public Health, Environmental Health Branch, to help San Francisco prepare for heat emergencies as a result of global warming.

Created in partnership with Garrow Consulting LLC, this is a self-directed presentation adapted from a data workshop commissioned by the city of Palm Springs, CA to help people better understand the flood of information out there about COVID-19.

Meeting of the College on Problems of Drug Dependence (CPDD) - Virtual - June 2020

International AIDS Conference - Amsterdam, The Netherlands - July 2018

9th IAS Conference on HIV Science (HIV/HCV Co-Infection Pre-conference) - Paris, France - July 2017

Created for the Infectious Disease Emergency Unit, Communicable Disease Control and Prevention Section of the San Francisco Department of Public Health - January 2010

CDC/APHL HIV Diagnostics Conference - Orlando, FL - March 2010

Facente SN, Grinstein R, Broussard J, Shost J, Azari S, Siruno J, Jimenez JA, Luetkemeyer AF, Burk K. Public Health Reports. 2022 Apr 9. doi: 10.1177/00333549221083741.

Facente SN, Grebe E, Maher AD, Fox D, Scheer S, Mahy M, Dalal S, Lowrance D, Marsh K. JMIR Public Health Surveillance. 2022 Mar 11; 8(3):e34410.

Bhatta DN, Hecht J, Facente SN. Sexually Transmitted Infections. 2022 Feb 4:sextrans-2021-055296.

Facente SN, Lam-Hine T, Bhatta DN, Hecht J. American Journal of Epidemiology. 2022 Mar 24; 191(4): 689-695.

Facente SN, Reiersen AM, Lenze EJ, Boulware DR, Klausner JD. Drugs. 2021 Dec; 81(18): 2081-2089.

Ahmad SR, Ahmad TR, Balasubramanian V, Facente S, Kin C, Girod S. Journal of Women's Health. 2021 Nov 5. doi: 10.1089/jwh.2021.0169.

Tan JY, Greene M, Blat C, Albers A, Grochowski J, Oskarsson J, Shiels M, Hsue P, Havlir D, Gandhi M, Myers J. AIDS & Behavior. 2022 May;26(5):1562-1571.

Mirzazadeh A, Facente SN, Burk K, Kahn JG, Morris MD; End Hep C SF. Annals of Epidemiology. 2022 Jan; 65: 59-64.

Facente SN, Hunter LA, Packel LJ, Li Y, Harte A, Nicolette G, McDevitt S, Petersen M, Reingold AL. BMC Public Health. 2021 Sep 16; 21(1): 1693.

Häberle AD, Nath R, Facente SN, Albers AE, Girod S. Craniomaxillofacial Trauma & Reconstruction. 2021 Sep; 14(3): 189-195.

Facente SN, Patel S, Hecht J, Wilson E, McFarland W, Page K, Vickerman P, Fraser H, Burk K, Morris MD. Clinicial Infectious Diseases. 2021 Sep 15;73(6):e1290-e1295.

Bhatta DN, Hecht J, Facente SN. International Journal of Environmental Research and Public Health. 2021; 18(5):8031.

Bates MN, Pope K, Sijali TR, Albers AE, Verma SC. Zoonoses Public Health. 2021; 00:1-8.

Packel L, Reingold A, Hunter L, Facente SN, Li Y, Harte A, Nicolette G, Urnov FD, Lu M, Petersen M. PLoS ONE. 2021; 16(1): e0245765.

Facente SN, Grebe E, Pilcher CD, Busch MP, Murphy G, Welte A. Epidemiology & Infection. 2020; 148: e53.

Gupta S, Scheuter C, Kundu A, Bhat N, Cohen A, Facente SN. American Journal of Preventive Medicine. 2020; 58(2): 261-269.

Grebe E, Facente SN, Bingham J, Pilcher CD, Powrie A, Gerber J, Priede G, Chibawara T, Busch MP, Murphy G, Kassanjee R, Welte, A, and the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). BMC Infectious Diseases. October 26, 2019, 18(894).

Facente SN, Busch MP, Grebe E, Pilcher CD, Welte A, Rice B, Murphy G. Gates Open Research. July 23, 2019, 3(1511). doi: https:// doi.org/10.12688/gatesopenres.13048.1.

Sempa JB Welte A, Busch MP, Hall J, Hampton D, Keating SM, Facente SN, Marson K, Parkin N, Pilcher CD, Murphy G, Grebe E; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). Plos ONE. July 26, 2019, 14(7): e0220345.

Albers AE, Pope K, Sijali TR, Subramanya SH, Verma SC, Bates MC. Environmental Research. June 2019, 173: 69-76.

Pilcher CD, Porco TC, Facente SN, Grebe E, Delaney KP, Masciotra S, Kassanjee R, Busch MP, Murphy G, Owen SW, Welte A; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). AIDS. June 1, 2019, 33(7): 1231-1240.

Strauli N, Fryer EK, Pham O, Abdel-Mohsen M, Facente SN, Pilcher C, Pennings P, Pillai S, Hernandez RD. The genetic interaction between HIV and the antibody repertoire. bioRxiv. May 23, 2019. doi:10.1101/646968.

Facente SN, Burk K, Eagen K, Mara ES, Smith AA, Lynch CS. Infectious Disease Clinics of North America. June 2018, 32(2): 313-322.

Gaudino A, Gay B, Garmon C, Selick M, Vreeland R, Burk K, Huriaux E, Facente SN, Luetkemeyer A, Waters P, Graham CS. Infectious Disease Clinics of North America. June 2018, 32(2): 293-311.

Facente SN, Grebe E, Burk K., Morris MD, Murphy E, Mirzazadeh A, Smith A, Sanchez M, Evans J, Nishimura A, Raymond HF. PLoS One. April 11, 2018, 13(4): e0195575.

Seaton KE, Vandergrift NA, Deal AW, Rountree W, Bainbridge J, Grebe E, Anderson DA, Sawant S, Shen X, Yates NL, Denny TN, Liao H-X, Haynes BF, Robb ML, Parkin N, Santon BR, Garrett N, Price MA, Naniche D, Duerr AC, Keating S, Hampton D, Facente S, Marson K, Welte A, Pilcher CD, Cohen MS, Tomaras GD. JCI Insight, December 22, 2017; 2(24): e94355.

Grebe E, Welte A, Hall J, Keating SM, Facente SN, Marson K, Martin JN, Little SJ, Price MA, Kallas EG, Busch MP, Pilcher CD, Murphy G; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). J Acquir Immune Defic Syndr, December 15, 2017; 76(5):547-555.

Keating SM, Pilcher CD, Jain V, Lebedeva M, Hampton D, Abdel-Mohsen M, Deng X, Murphy G, Welte A, Facente SN, Hecht F, Deeks SG, Pillai SK, Busch MP. Journal of Infectious Diseases. 2017, 216:72–81.

Schlusser KE, Pilcher C, Kallas EG, Santos BR, Deeks SG, Facente S, Keating SM, Busch MP, Murphy G, Welte A, Quinn T, Eshleman SH, Laeyendecker O. PLoS One, February 23, 2017, 12(2):e0172283.

Murphy G, Pilcher CD, Keating SM, Kassanjee R, Facente SN, Welte A, Grebe E, Marson K, Busch MP, Dailey P, Parkin N, Osborn J, Ongarello S, Marsh K, Garcia-Calleja JM; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA), Foundation for Innovative New Diagnostics, UNAIDS, and the WHO Technical Working Group. Epidemiology & Infection, 2017 Apr, 145(5): 925-941.

Keating SM, Kassanjee R, Lebedeva M, Facente SN, MacArthur JC, Grebe E, Murphy G, Welte A, Martin JN, Little S, Price MA, Kallas EG, Busch MP, Pilcher CD; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). J Acquir Immune Defic Syndr, December 15, 2016, 73(5): 581-588.

Kassanjee R, Pilcher CD, Busch MP, Murphy G, Facente SN, Keating SM, McKinney E, Marson K, Price MA, Martin JN, Little SJ, Hecht FM, Kallas EG, Welte A; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). AIDS, 2016, 30:2361-2371.

Delaney KP, Rurangirwa J, Facente S, Dowling T, Janson M, Knoble T, Vu A, Hu YW, Kerndt PR, King J, Scheer S. J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):78-86.

Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA, Martin JN, Little S, Hecht FM, Kallas EG, Welte A, Busch MP, and Murphy G. AIDS, October 23, 2014, 28(16): 2439-2449.

Pilcher CD, Louie B, Facente S, Keating S, Hackett J, Vallari A, Hall C, Dowling T, Busch MP, Klausner JD, Hecht FM, Liska S, Pandori MW. PLoS ONE, December 2013, 8(12): e80629. doi:10.1371/journal.pone.0080629.

Facente, SN, Pilcher, CD, Hartogensis, WE, Klausner, JD, Philip, SS, Louie, B, Christopoulos, KA, Dowling T, and Colfax GN. PLoS ONE, July 2011, 6(7): e21813. doi:10.1371/journal.pone.0021813

Sheon N, Lee S-H, and Facente SN. Patient Education and Counseling, December 2010, 81(3): 468-475.

Facente, SN, Dowling, T, Vittinghoff, E, Sykes, DL, and Colfax, GN. PLoS ONE, December 2009, 4(12): e8217. doi:10.1371/journal.pone.0008217. PLoS ONE, December 2009, 4(12): e8217. doi:10.1371/journal.pone.0008217

Breckwich-Vásquez, V, Lanza, D, Hennessey-Lavery, S, Facente, S, Halpin, HA, and Minkler, M. Health Promotion Practice, October 2007, 8(4): 342-349.

Minkler, M, Breckwich-Vásquez, V, Rains-Warner, J, Steussey, H, Facente, SN. Health Promotion International, December 2006, 21(4): 293-300.

Wesolowski, LG, MacKellar, DA, Facente, SN, Dowling, T, Ethridge, SF, Zho, JH, and Sullivan, PS. AIDS, August 2006, 20(12):1661-1666.